Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan.
Ogawa K, Koh Y, Kaneda H, Izumi M, Matsumoto Y, Sawa K, Fukui M, Taniguchi Y, Yoshimoto N, Tamiya A, Ando M, Kubo A, Isa SI, Saka H, Matsumura A, Kawaguchi T. Ogawa K, et al. Among authors: yoshimoto n. BMJ Open. 2020 Sep 9;10(9):e035615. doi: 10.1136/bmjopen-2019-035615. BMJ Open. 2020. PMID: 32907893 Free PMC article.
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K. Yoshimura N, et al. Among authors: yoshimoto n. Lung Cancer. 2015 Oct;90(1):65-70. doi: 10.1016/j.lungcan.2015.06.002. Epub 2015 Jun 15. Lung Cancer. 2015. PMID: 26238424 Clinical Trial.
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Among authors: yoshimoto n. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa S, Saka H, Matsumura A. Kawaguchi T, et al. Among authors: yoshimoto n. J Clin Oncol. 2016 Jul 1;34(19):2247-57. doi: 10.1200/JCO.2015.64.2322. Epub 2016 May 9. J Clin Oncol. 2016. PMID: 27161973
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Matsumoto Y, Kawaguchi T, Yamamoto N, Sawa K, Yoshimoto N, Suzumura T, Watanabe T, Mitsuoka S, Asai K, Kimura T, Yoshimura N, Kuwae Y, Hirata K. Matsumoto Y, et al. Among authors: yoshimoto n. Intern Med. 2017 Sep 1;56(17):2325-2328. doi: 10.2169/internalmedicine.8467-16. Epub 2017 Aug 10. Intern Med. 2017. PMID: 28794368 Free PMC article.
Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K. Yoshimura N, et al. Among authors: yoshimoto n. Am J Clin Oncol. 2018 Oct;41(10):967-971. doi: 10.1097/COC.0000000000000412. Am J Clin Oncol. 2018. PMID: 29045265 Clinical Trial.
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Sawa K, Koh Y, Kawaguchi T, Kambayashi S, Asai K, Mitsuoka S, Kimura T, Yoshimura N, Yoshimoto N, Kubo A, Saka H, Matsumura A, Wanibuchi H, Yamamoto N, Nishiyama N, Hirata K. Sawa K, et al. Among authors: yoshimoto n. Lung Cancer. 2017 Oct;112:96-101. doi: 10.1016/j.lungcan.2017.07.039. Epub 2017 Aug 7. Lung Cancer. 2017. PMID: 29191607
Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy.
Yamamoto N, Watanabe T, Yamada K, Nakai T, Suzumura T, Sakagami K, Yoshimoto N, Sato K, Tanaka H, Mitsuoka S, Asai K, Kimura T, Kanazawa H, Hirata K, Kawaguchi T. Yamamoto N, et al. Among authors: yoshimoto n. J Thorac Dis. 2019 Mar;11(3):936-943. doi: 10.21037/jtd.2019.01.88. J Thorac Dis. 2019. PMID: 31019783 Free PMC article.
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Hirata K, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: yoshimoto n. Lung Cancer. 2020 Jan;139:80-88. doi: 10.1016/j.lungcan.2019.10.029. Epub 2019 Nov 2. Lung Cancer. 2020. PMID: 31751804
358 results